I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $330.575M

Company

Location

Date

Amt. (M)

Details

Alnylam
Pharmaceuticals
Inc.

Cambridge,
Mass.

7/7

$24.6

Alnylam raised $24.6M in a private financing; investors were Polaris Venture Partners, Abingworth Management, Cardinal Partners, Atlas Venture and ARCH Venture Partners

Angiogenix I
nc.

Burlingame,
Calif.

7/24

$3

Angiogenix raised $3M in a Series C preferred stock financing made by RBC Capital Partners

Ardana
Bioscience Ltd.

Edinburgh,
UK

7/30**

£20
(US
$32.3)

Ardana raised US$32.3M in a Series B round led by Techno Venture Management; other investors were ISIS Equity Partners plc, Merlin Biosciences Ltd., MVM Ltd., ABN-AMRO Participates BV, 3i and Green Highlander LLC

Arexis AB

Stockholm,
Sweden

7/1

SEK63
(US$7.9)

Arexis raised US$7.9M in the financing

Bionaut
Pharma-
ceuticals Inc.

Cambridge,
Mass.

7/8

$6.8

Bionaut raised $6.8M in a Series A financing with investors Collinson, Howe & Lennox and HealthCap Venture Capital

Cohesive
Technologies
Inc.

Franklin,
Mass.

7/1

$1

Cohesive raised a total of $9.5M in a private financing begun in April; $8.5M of the financing was accounted for in the April chart

Immunicon
Corp.

Huntingdon
Valley, Pa.

7/10

$25

Immunicon raised $25M in the financing; investors were TL Ventures, Claneil Enterprises Inc., Johnson & Johnson Development Corp., Canaan Partners, Anthem Capital, Burrill & Co., Foundation Medical Partners, Wheatley Partners, MDS Capital Corp., The Cleveland Clinic Foundation, equity4Life and MedCapital Investments

Innodia Inc.

Montreal

7/28

C$3
(US$2.2)

Innodia raised another US$2.2M in a private financing begun in May; the total amount raised is C$10M (US$7.2M); CDP Capital-Technology Ventures was the latest investor

Intercell AG

Vienna,
Austria

7/23**

€30
(US
$34.6)

Intercell raised US$34.6M in a third round led by Global Life Science Ventures; other investors were Apax Partners Funds, Nomura, TVM and NIB Capital, as well as STAR Ventures

Ionix Pharma-
ceuticals Ltd.

Cambridge,
Mass.

7/16

£10
(US
$15.9)

Ionix raised US$15.9M through a Series B financing; investors included Apax Partners and The Wellcome Trust

Milkhaus
Laboratory
Inc.

Providence,
R.I.

7/28

$5.8

Milkhaus raised $5.8M in equity capital through a rights offering to its current shareholders

Onco-
Methylome
Sciences SA

Liege,
Belgium

7/15

€14
(US
$15.6)

OncoMethylome raised US$15.6M with investors ING Belgium, Polytechnos Venture Partners, Life Sciences Partners, Technowal, Meusinvest and S.I.B.L., as well as members of management

PamGene
International
BV

's-Hertogenbosch,
the Netherlands

7/7

€10
(US
$11.34)

PamGene raised US$11.34M in a second financing round with investors LCF Rothschild Venture Partners, Alta Partners, GIMV and LSP

Santarus
Inc.

San Diego

7/15

$3.7

Santarus raised another $3.7M in its Series D financing round, bringing the total raised to $55.1M

Speedel
Group

Basel,
Switzerland

7/9**

CHF52.1
(US
$38.7)

Speedel Group raised US$38.7M in a mezzanine financing round

Tercica Inc.

South San
Francisco

7/17

$44

Tercica raised $44M in a second round; investors were Rho Ventures, Care Capital LLC, MedImmune Ventures Inc., MPM Capital and Prospect Venture Partners

Therascope
AG

Heidelberg,
Germany

7/18

€24.1
(US
$27.8)

Therascope raised US$27.8M in a second round; investors were Earlybird Venture Capital, Schroder Ventures Life Sciences, ABN AMRO, Ventech, Auriga Ventures and Heidelberg Innovation

TransOral
Pharma-
ceuticals Inc.

San Rafael,
Calif.

7/24

$7.5

TransOral raised $7.5M in a Series B round led by Montreux Equity Partners; other investors were Hamilton Apex Technology Ventures, BioAsia Investments and Peninsula Equity Partners

Xcellsyz
Ltd.

Newcastle,
UK

7/3

£0.5
(US
$0.835)

Xcellsyz raised US$835,000 from investors NEL Ltd. and ITX Corp.

Xenogen
Corp.

Alameda,
Calif.

7/11

$22

Xenogen raised $22M after closing a preferred equity financing led by Abingworth Management

II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $6.912M

Company (Symbol)#*

Partner
(Country)

Amt. (M)

Triggering Event

Details (Date)

Abgenix Inc.
(ABGX)

Pfizer Inc.

ND

Milestone payment

Abgenix received the payment for Pfizer's filing of an investigational new drug application with the FDA for an antibody product candidate (7/16)

Guilford
Pharmaceuticals
Inc. (GLFD)

Daiichi
Radioisotope Laboratories (Japan)

$0.55

Milestone payment

Guilford received the payment when Daiichi filed for approval of Dopascan injection in Japan (7/10)

ImClone
Systems Inc.
(IMCL)

Merck KgaA
(Germany)

$6

Milestone payments

ImClone received $6M through two milestones triggered by Merck's submission of marketing applications for Erbitux for metastatic colorectal cancer in the European Union and Switzerland (7/15)

Pharmacopeia
Inc. (PCOP)

Celgene
Corp.

ND

Milestone payment

Pharmacopeia earned a milestone payment for discovering lead compounds from its compound collection active against Celgene's inflammation-related kinase target (7/22)

Transition
Therapeutics
Inc. (Canada;
VSE:TTH)

Novo Nordisk
A/S (Denmark)

C$0.5
(US
$0.362)

Investment

Transition Therapeutics received an investment of US$362,000 after selling about 1.1M common shares to Novo Nordisk (7/25)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Denotes privately held company.

** Denotes the date the item ran in BioWorld International.

ND = Not disclosed.

VSE = Vancouver Stock Exchange.